Claims for Patent: 11,273,131

Summary for Patent: 11,273,131

Title:	Pharmaceutical compositions with enhanced permeation
Abstract:	Pharmaceutical compositions having enhanced active component permeation properties are described.
Inventor(s):	Schobel Alexander Mark, Varjan Stephanie Marie, Wargacki Stephen Paul
Assignee:	AQUESTIVE THERAPEUTICS, INC.
Application Number:	US15724234
Patent Claims:	1. A pharmaceutical composition , comprising:a polymeric matrix comprising a polyethylene oxide, a cellulosic polymer, a hydroxypropyl methylcellulose, a polyvinylpyrrolidone, a polysaccharide, a polyethylene oxide and a polyvinylpyrrolidone, a polyethylene oxide and a polysaccharide, a polyethylene oxide, and hydroxypropyl methylcellulose and a polysaccharide, a polyethylene oxide and a hydroxypropyl methylcellulose and a polysaccharide and a polyvinylpyrrolidone, a cellulosic polymer and a polysaccharide, a cellulosic polymer and a polyvinylpyrrolidone, a hydroxypropyl methylcellulose and polyvinylpyrrolidone, a dendritic polymer, or a hyperbranched polymer;a pharmaceutically active component including a benzodiazepine in the polymeric matrix; andan adrenergic receptor interacter.2. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition further includes a permeation enhancer.3. The pharmaceutical composition according to claim 1 , wherein the adrenergic receptor interacter includes a terpenoid claim 1 , a terpene claim 1 , or a sesquiterpene.4. The pharmaceutical composition according to claim 2 , wherein the permeation enhancer includes farnesol or Labrasol.5. The pharmaceutical composition according to claim 2 , wherein the permeation enhancer includes linoleic acid.6. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a film further comprising a polymeric matrix claim 1 , the pharmaceutically active component being contained in the polymeric matrix.7. The pharmaceutical composition according to claim 1 , wherein the adrenergic receptor interacter includes a phenylpropanoid.8. The pharmaceutical composition according to claim 7 , wherein the phenylpropanoid is eugenol or eugenol acetate.9. The pharmaceutical composition according to claim 7 , wherein the phenylpropanoid is a cinnamic acid claim 7 , cinnamic acid ester claim 7 , cinnamic aldehyde or hydrocinnamic acid.10. The pharmaceutical composition according to claim 7 , wherein the phenylpropanoid is chavicol.11. The pharmaceutical composition according to claim 7 , wherein the phenylpropanoid is safrole.12. The pharmaceutical composition according to claim 1 , wherein the adrenergic receptor interacter is a phytoextract.13. The pharmaceutical composition according to claim 12 , wherein the phytoextract further includes an essential oil extract of a clove plant.14. The pharmaceutical composition according to claim 12 , wherein the phytoextract further includes an essential oil extract of a leaf of a clove plant.15. The pharmaceutical composition according to claim 12 , wherein the phytoextract further includes an essential oil extract of a flower bud of a clove plant.16. The pharmaceutical composition according to claim 12 , wherein the phytoextract further includes an essential oil extract of a stem of a clove plant.17. The pharmaceutical composition according to claim 12 , wherein the phytoextract is synthetic or biosynthetic.18. The pharmaceutical composition according to claim 12 , wherein the phytoextract further includes 40-95% eugenol.19. The pharmaceutical composition according to claim 1 , wherein the polymer matrix includes a water soluble polymer.20. The pharmaceutical composition according to claim 1 , wherein the polymer matrix includes a cellulosic polymer selected from the group of: hydroxyethyl cellulose claim 1 , hydroxyethylmethyl cellulose claim 1 , hydroxypropyl cellulose claim 1 , hydroxypropyl methylcellulose claim 1 , and carboxymethyl cellulose.21. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a chewable or gelatin based dosage form claim 1 , spray claim 1 , gum claim 1 , gel claim 1 , cream claim 1 , tablet claim 1 , liquid or film.22. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix comprises a polyethylene oxide claim 1 , cellulosic polymer claim 1 , polyethylene oxide and polyvinyl pyrrolidone claim 1 , polyethylene oxide and a polysaccharide claim 1 , polyethylene oxide claim 1 , hydroxypropyl methylcellulose and a polysaccharide claim 1 , or polyethylene oxide claim 1 , hydroxypropyl methylcellulose claim 1 , polysaccharide and polyvinylpyrrolidone.23. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix further comprises at least one polymer selected from the group of: pullulan claim 1 , polyvinyl pyrrolidone claim 1 , polyvinyl alcohol claim 1 , sodium alginate claim 1 , polyethylene glycol claim 1 , xanthan gum claim 1 , tragancanth gum claim 1 , guar gum claim 1 , acacia gum claim 1 , arabic gum claim 1 , polyacrylic acid claim 1 , methylmethacrylate copolymer claim 1 , carboxyvinyl copolymers claim 1 , starch claim 1 , gelatin claim 1 , ethylene oxide claim 1 , propylene oxide co-polymers claim 1 , collagen claim 1 , albumin claim 1 , poly-amino acids claim 1 , polyphosphazenes claim 1 , polysaccharides claim 1 , chitin claim 1 , and chitosan.24. The pharmaceutical composition according to claim 1 , further comprising a stabilizer.25. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix comprises a dendritic polymer or a hyperbranched polymer.26. A pharmaceutical composition claim 1 , comprising:a polymeric matrix comprising a cellulosic polymer, a hydroxypropyl methylcellulose, polyvinylpyrrolidone, a polysaccharide, a polyethylene oxide, polyethylene oxide and polyvinyl pyrrolidone, polyethylene oxide and a polysaccharide, polyethylene oxide and hydroxypropyl methylcellulose and a polysaccharide, polyethylene oxide and hydroxypropyl methylcellulose and a cellulosic polymer and a polysaccharide, a cellulosic polymer and a polyvinylpyrrolidone, a polysaccharide and a polyvinylpyrrolidone, a hydroxypropyl methylcellulose and a polyvinylpyrrolidone, a dendritic polymer or a hyperbranched polymer;a stabilizer;a pharmaceutically active component including a benzodiazepine in the polymeric matrix; andan adrenergic receptor interacter.27. The pharmaceutical composition according to claim 26 , wherein the adrenergic receptor interacter includes eugenol or eugenol acetate.28. The pharmaceutical composition according to claim 26 , wherein the adrenergic receptor interacter includes a cinnamic acid claim 26 , cinnamic acid ester claim 26 , cinnamic aldehyde or hydrocinnamic acid.29. The pharmaceutical composition according to claim 26 , wherein the adrenergic receptor interacter includes chavicol.30. The pharmaceutical composition according to claim 26 , wherein the adrenergic receptor interacter includes safrole.31. The pharmaceutical composition according to claim 26 , wherein the adrenergic receptor interacter includes an essential oil extract of a clove plant.32. The pharmaceutical composition according to claim 26 , wherein the adrenergic receptor interacter includes an essential oil extract of a leaf of a clove plant.33. The pharmaceutical composition according to claim 26 , wherein the adrenergic receptor interacter includes an essential oil extract of a flower bud of a clove plant.34. The pharmaceutical composition according to claim 26 , wherein the adrenergic receptor interacter includes an essential oil extract of a stem of a clove plant.35. The pharmaceutical composition according to claim 26 , wherein the phytoextract is synthetic or biosynthetic.36. The pharmaceutical composition according to claim 26 , wherein the adrenergic receptor interacter includes 40-95% eugenol.37. The pharmaceutical composition according to claim 26 , wherein the polymer matrix includes a cellulosic polymer selected from the group of: hydroxyethyl cellulose claim 26 , hydroxyethylmethyl cellulose claim 26 , hydroxypropyl cellulose claim 26 , hydroxypropyl methylcellulose claim 26 , and carboxymethyl cellulose.38. The pharmaceutical composition according to claim 26 , wherein the polymeric matrix comprises a polyethylene oxide claim 26 , cellulosic polymer claim 26 , polyethylene oxide and polyvinyl pyrrolidone claim 26 , polyethylene oxide and a polysaccharide claim 26 , polyethylene oxide and hydroxypropyl methylcellulose and a polysaccharide claim 26 , or polyethylene oxide and hydroxypropyl methylcellulose claim 26 , and polysaccharide and polyvinylpyrrolidone.39. The pharmaceutical composition according to claim 26 , wherein the polymeric matrix comprises a dendritic polymer claim 26 , or a hyperbranched polymer.40. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix comprises a polyethylene oxide.41. The pharmaceutical composition according to claim 26 , wherein the polymeric matrix comprises a polyethylene oxide.42. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix comprises a polyvinylpyrrolidone.43. The pharmaceutical composition according to claim 26 , wherein the polymeric matrix comprises a polyvinylpyrrolidone.44. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix comprises a polysaccharide.45. The pharmaceutical composition according to claim 26 , wherein the polymeric matrix comprises a polysaccharide.46. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix comprises a cellulosic polymer and a polysaccharide.47. The pharmaceutical composition according to claim 26 , wherein the polymeric matrix comprises a cellulosic polymer and a polysaccharide.48. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix comprises a cellulosic polymer and polyvinylpyrrolidone.49. The pharmaceutical composition according to claim 26 , wherein the polymeric matrix comprises a cellulosic polymer and polyvinylpyrrolidone.50. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix comprises a hydroxypropyl methylcellulose and a polyvinylpyrrolidone.51. The pharmaceutical composition according to claim 26 , wherein the polymeric matrix comprises a hydroxypropyl methylcellulose and a polyvinylpyrrolidone.52. The pharmaceutical composition according to claim 1 , further comprising benzyl alcohol.53. The pharmaceutical composition according to claim 26 , further comprising benzyl alcohol.54. The pharmaceutical composition according to claim 1 , wherein the benzodiazepine is diazepam.55. The pharmaceutical composition according to claim 26 , wherein the benzodiazepine is diazepam.56. A pharmaceutical composition claim 26 , comprising:a polymeric matrix comprising a cellulosic polymer, a polyvinylpyrrolidone, or a cellulosic polymer and a polyvinylpyrrolidone;a pharmaceutically active component including diazepam in the polymeric matrix; andan adrenergic receptor interacter.57. The pharmaceutical composition according to claim 56 , wherein the adrenergic receptor interacter includes eugenol claim 56 , eugenol acetate claim 56 , clove oil claim 56 , a cinnamic acid claim 56 , cinnamic acid ester claim 56 , cinnamic aldehyde claim 56 , or hydrocinnamic acid.58. The pharmaceutical composition according to claim 56 , further comprising benzyl alcohol.